Type 3 hypersensitivity in COVID-19 vasculitis

Author links open overlay panelLucaRoncatiabcGiuliaLigabuedLucaFabbianiacClaudiaMalagoliacGrazianaGalloaBeatriceLusentibVincenzoNasillobAntonioManentieAntonioMaioranaa Show more

https://doi.org/10.1016/j.clim.2020.108487Get rights and content

Highlights •COVID-19 is an ongoing public health emergency around the world.•New knowledge about its immunopathogenic mechanisms is required.•Type 3 hypersensitivity reaction in COVID-19 vasculitis is here disclosed.•Inflamed vascular smooth muscle cells concur to the cytokine storm via IL-6.•Histology, histochemistry and immunofluorescence have been successfully applied.

Abstract Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden, globally. For the first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening escalation from type 2 T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine, from the smooth muscle cells of blood vessels.

Keywords Coronavirus disease 2019 (COVID-19) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Type III hypersensitivity Immune complex disease Vasculitis Interleukin-6 (IL-6)

Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency around the world and the acquisition of new knowledge about its immunopathogenesis is required in the attempt to reduce the death burden, globally. As well known, naїve T-helper cells (Th0) can detect pathogens never encountered before, like the specific case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the disease, able to infect the human cells via angiotensin-converting enzyme 2 receptors [1]. Classically, on the basis of the novel infectious agent, Th0 polarize the immune response into type 1 T-helper (Th1), the default response in immunocompetent subjects to intracellular or phagocytosable pathogens (e.g. viruses, bacteria, protozoa, fungi) and mediated by macrophages and T-cytotoxic (Tc) cells (cell-mediated immunity), or into type 2T-helper (Th2), typically directed against extracellular non-phagocytosable pathogens, for instance helminths, and whose main effectors are eosinophils, basophils and mastocytes, as well as B cells (humoral immunity) [2]. The ultimate goal of humoral immunity is to produce opsonising antibodies and to generate memory cells able to promptly counteract the pathogen in the future, if necessary [3]. During our researches on COVID-19, we have disclosed that, for reasons still unclear and maybe related to the viral load or to Th1 and Tc breakdown, the immune system is forced to mount a Th2 response against SARS-CoV-2 in patients requiring intensive care, rather than a Th1 response, which would keep the infection under control by means of macrophages and Tc cells [4].

According to Gell and Coombs classification, type 3 hypersensitivity takes place when an excess or slight excess of soluble antigens lead to the accumulation of immune complexes, not enough cleared from the circulation by the innate immune system [5]. These antigen-antibody complexes precipitate inside the tissues, in particular blood vessels, inducing a severe inflammatory state by the action of complement anaphylatoxins (C3a and C5a), which in turn stimulate the release of histamine from mast cells and the recruitment of phagocytes, in primis neutrophils, the main responsible for the tissue damage [5]. On histopathology, the result of this process inside the walls of blood vessels is depicted by an acute necrotizing vasculitis with neutrophilic infiltration, karyorrhexis and fibrinoid necrosis, the so called «leukocytoclastic vasculitis» (LCV), also reported in the English medical literature by the term «hypersensitivity vasculitis» [6]; platelet aggregation correlates with hypercoagulability and thrombosis, disorders described in course of COVID-19, too [7]. The just mentioned fibrinoid necrosis represents a specific pattern of tissue injury, which occurs once antigen-antibody complexes are deposited in the walls of blood vessels along with fibrin and complement anaphylatoxins; therefore, it can be considered a diagnostic clue of immune-mediated vasculitides from type 3 hypersensitivity [8]. LCV is preceded by a viral infection, such as hepatitis B, hepatitis C and HIV, in a relevant percentage of cases [6].

The onset time of type 3 hypersensitivity varies from days to weeks depending on the presence or not of memory cells against the precipitating antigen; clinical features emerge approximately 10 days after initial antigenic challenge [8]. During the Severe Acute Respiratory Syndrome (SARS) outbreak in 2002–2003, caused by SARS-CoV-2 predecessor (SARS-CoV), it was observed that the acute respiratory distress syndrome, one the most serious complications of the disease, significantly overlapped with antiviral immunoglobulin G (IgG) seroconversion [9]; besides, it was found that patients who developed more quickly the anti-spike neutralizing antibody showed a higher risk of dying from the disease [10]. Translating our current findings on COVID-19, these alarming data can be now explained for the first time in worldwide literature by a life-threatening escalation from Th2 immune response to type 3 hypersensitivity with the subsequent deposition of antigen-antibody complexes, particularly inside the walls of blood vessels, to such an extent as to generate a systemic vasculitis in the context of an immune complex disease (Fig. 1). This event is accompanied by complement C3 activation, which is positioned upstream of the thrombo-inflammatory complement cascade in COVID-19; therefore, to prevent C3 activation into C3a anaphylatoxin through specific inhibitors, like compstatin-based AMY-101, can provide effective therapeutic results [11]. Preexisting endothelial dysfunctions due to atherosclerosis could worsen the deposition process in elderly and middle-aged patients [12]; since the smooth muscle cells in tunica media of blood vessels are able to produce interleukin-6 (IL-6) [13], a key myokine of inflammation and of the cytokine release syndrome, their inflammatory involvement can justify well the described «cytokine storm» in COVID-19 critical patients, a dramatic phenomenon remained not fully elucidated up to date.